Table 1.

Recruitment and characteristics of study population in the BLITZ sample evaluating FOB Gold compared to the MSDT study evaluating Cologuard⁷

Recruitment		MSDT study evaluation of Cologuard7		BLITZ study evaluation of FOB Gold®
		June 2011–November 2012, private practices and academic centers in the US and Canada		November 2008–September 2014, private practices in Germany
Characteristics of study population		n	%	n	%
Sex	Male	4625	46.3	1737	49.7
	Female	5364	53.7	1757	50.3
Age, years	50–54	2862	28.7	98	2.8
	55–59			1514	43.3
	60–64	819	8.2	735	21.0
	65–69	3670	36.7	535	15.3
	70–74	1735	17.4	447	12.8
	75–84	903	9.0	165	4.7
Most advanced finding at screening colonoscopy	CRC	65	0.65	30	0.86
	Stage I	29	0.29	10	0.29
	Stage II	21	0.21	4	0.11
	Stage III	10	0.10	13	0.37
	Stage IV	4	0.04	3	0.09
	APCL#	757	7.58	359	10.27
	≥1 cm	691	6.92	276	7.90
	<1 cm	66	0.66	83	2.37
	Non-advanced adenoma	2893	28.96	688	19.69
	None of the above	6274	62.81	2417	69.18

Note:

^#APCLs, including advanced adenomas and sessile serrated polyps ≥1 cm.

Abbreviations: MSDT, multitarget stool DNA test; CRC, colorectal cancer; APCL, advanced precancerous lesion.